FRANKLIN LAKES, N.J.,
Feb. 16, 2017 /PRNewswire/ -- BD
(Becton, Dickinson and Company) (NYSE: BDX), a leading global
medical technology company, today announced a new alliance
dedicated to help address the rising opioid crisis in acute care
settings.
Comprised of top health systems and industry leaders, the
alliance is a new initiative stemming from the recently launched BD
Institute for Medication Management Excellence. The industry
alliance will expand on the key initiatives established by the BD
Institute: Opioid Control and Management, End-to-End IV Safety and
Medication Availability – concentrating on identifying effective
ways of tracking controlled substances across the entire end-to-end
medication management process with the ability to detect, monitor
and ultimately reduce drug diversion. The initiative was
inaugurated during the 2016 American Society of Health Systems
Pharmacists (ASHP) Midyear Meeting with the premise of promoting
innovation in medication management through collaboration between
BD, electronic health record (EHR) vendors and leveraging the
insights from customers and industry thought leaders.
"This alliance of remarkably innovative health systems is
focused on addressing the challenges of opioid use, including the
risk of drug diversion and is a great example of how thought
leaders in health care can partner to address some of the most
important challenges in our industry," said Ranjeet Banerjee, worldwide president of
Medication Management Solutions for BD. "In our efforts to advance
the world of health, BD recognizes that drug diversion is a health
and safety issue for providers and patients. We believe it's
crucial to actively drive collaboration, policy and best practices
together with health care providers across the nation to reduce
diversion and increase patient safety."
According to the Centers for Disease Control and Prevention
(CDC), the amount of prescription opioids sold in the U.S. nearly
quadrupled since 1999i, costing the U.S. an estimated
$55 billionii in health
and social costs every year. Acute care providers are on the
frontlines of this public health epidemic every day as a result of
drug diversion.
"Hospitals are on the frontline of monitoring and working to
prevent drug diversion within their facilities," said Perry Flowers, vice president, Acute &
Transitional Care at Kaiser Permanente, one of the founding members
of the alliance. "Now is the time for health systems and industry
to unite to drive innovation that will address this epidemic.
Collaboration between our EHR vendor and BD can lead to significant
innovation in patient care and medication management. One of these
areas is pursuing new ways to address accountability for controlled
drugs in hospitals. To that end, we are extremely pleased to join
with our industry peers in this initiative."
Debbie Simonson, vice president,
Pharmacy Services at Ochsner Health System said, "By bringing
industry leaders together we have a significant opportunity to
improve how controlled substances in acute care settings are
managed. By setting standards and integrating data from the EHR
with medication management systems, we will be able to detect,
monitor and ultimately reduce drug diversion. With no generally
accepted standards for monitoring opiate diversion in U.S.
hospitals, we feel it's critical to address this alarming epidemic
and partner with visionary colleagues and technology providers in
doing so."
For more information about BD's thought leadership programs,
please visit: www.bd.com/BDinstitute and www.bd.com/diversion.
About BD
BD is a global medical technology company
that is advancing the world of health by improving medical
discovery, diagnostics and the delivery of care. BD leads in
patient and health care worker safety and the technologies that
enable medical research and clinical laboratories. The company
provides innovative solutions that help advance medical research
and genomics, enhance the diagnosis of infectious disease and
cancer, improve medication management, promote infection
prevention, equip surgical and interventional procedures, and
support the management of diabetes. The company partners with
organizations around the world to address some of the most
challenging global health issues. BD has more than 40,000
associates across 50 countries who work in close collaboration with
customers and partners to help enhance outcomes, lower health care
delivery costs, increase efficiencies, improve health care safety
and expand access to health. For more information on BD, please
visit bd.com.
i CDC. Wide-ranging online data for epidemiologic
research (WONDER). Atlanta, GA:
CDC, National Center for Health Statistics; 2016. Available at
http://wonder.cdc.gov.
ii CDC, MMWR, 2015: 64: 1-5.
Matt
Coppola
|
Monique N.
Dolecki
|
BD Public
Relations
|
BD Investor
Relations
|
201.847.7370
|
201.847.5378
|
mailto:troy.kirkpatrick@bd.com
|
monique_dolecki@bd.com
|
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/bd-initiates-new-industry-alliance-to-combat-rising-opioid-crisis-300408523.html
SOURCE BD (Becton, Dickinson and Company)